BioSpace News Archive

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will host a company presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference to be held in Toronto, Ontario from April 25-26, 2023.

Vaxcyte, Inc. (Nasdaq: PCVX) announced today the closing of its previously announced underwritten public offering of 13,030,000 shares of common stock at a public offering price of $41.00 per share and pre-funded warrants to purchase 1,000,000 shares of common stock at a public offering price of $40.999 per underlying share.

Axsome Therapeutics, Inc. today announced that it will be presenting five abstracts at the upcoming 2023 American Academy of Neurology (AAN) Annual Meeting, being held from April 22-27 in Boston.

KORU Medical Systems today announced that the Company will report first quarter 2023 financial results on Thursday, May 4, 2023.

Dr. Reddy’s Laboratories Ltd. today announced the launch of Treprostinil Injection in the U.S. market, a therapeutic equivalent generic version of Remodulin® (treprostinil) Injection, approved by U. S. Food and Drug Administration (USFDA).

Satsuma Pharmaceuticals, Inc . today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology’s (AAN) 75th Annual Meeting.

LianBio today announced that China’s National Medical Products Administration (NMPA) has accepted with priority review the New Drug Application (NDA) for mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults.

Disc Medicine, Inc. announced today that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023 at 2:30 p.m.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that results from RELIEF-PHN-1, a Phase 2 double-blind, placebo-controlled trial of its investigational drug LX9211 for the treatment of postherpetic neuralgia, will be presented during the Emerging Science session at the AAN Annual Meeting, April 22-27, in Boston, MA.

Doheny Eye Institute announced that more than 30 of its scientists and clinician-scientists will present their latest research during the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The meeting will take place April 23-27, 2023 in New Orleans at the Ernest N. Morial Convention Center.